Who Owns 23andMe Company?

Who controls 23andMe today?

The founder’s bid to take 23andMe private in late 2024–early 2025 intensified scrutiny of ownership after market value fell from $3.5 billion in 2021 to under $200 million. Voting power rests with a dual-class structure and concentrated founder stakes, shaping strategy toward biotech and subscriptions.

Founded in 2006 in South San Francisco, 23andMe built a database of over 15 million genotyped people and shifted from kits to recurring 23andMe+ revenue amid investor pushback; see 23andMe Porter's Five Forces Analysis.

Founders and early ownership of 23andMe trace to its 2006 founding by Anne Wojcicki, Linda Avey, and Paul Cusenza; Wojcicki emerged as the enduring CEO and dominant owner after Avey left in 2009 and Cusenza in 2007.

Founding team roles

Anne Wojcicki led product and strategy; Linda Avey provided biotech expertise; Paul Cusenza handled early business operations.

Early ownership split

Initial equity was divided among the three founders and early employees with standard vesting schedules and protective provisions.

Key early investors

Google invested $3.9 million in 2007; New Enterprise Associates and Genentech were also early backers.

Venture financing through 2012

By Series D in 2012 the company had raised over $100 million, attracting firms like DST Global and Johnson & Johnson Development Corp.

Governance and data protection

Early agreements often required supermajority votes to protect the genetic database and prioritize long-term research over short-term exits.

Legacy and ownership tensions

Foundational equity and preferred rights created a governance model that shaped later disputes over 23andMe ownership and strategy.

Strategic investments from tech and biotech set the early course for 23andMe ownership, influencing later transactions, partnerships, and debates about corporate control.

Founders and early ownership facts

Key points on founders, investors, and early governance affecting 23andMe ownership and control.

• Co-founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza
• Google invested $3.9 million in 2007; NEA and Genentech were early backers
• Raised over $100 million by Series D in 2012 with investors including DST Global and J&J Development
• Early agreements required supermajority votes to protect the genetic database and research mission

See related analysis on company market positioning and customer segments: Target Market of 23andMe

Complete 23andMe Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Key events reshaping 23andMe ownership include the June 2021 SPAC merger with VG Acquisition Corp., the $3.5 billion valuation and nearly $600 million gross proceeds, a strategic shift via the $400 million Lemonaid Health acquisition, a late-2024 1-for-20 reverse split, and ownership dilution with institutional stakes falling by 2025.

The current ownership structure of 23andMe shows concentrated control via dual-class shareholding: founder Anne Wojcicki retains outsized voting influence despite ~20% economic stake, while institutional ownership fell from >45% at IPO to about 28% by early 2025, reflecting exits after prolonged sub-$1 trading and strategic pressure to monetize therapeutics and consider privatization.

Ownership Dynamics to Watch

Shifts in major stakeholders have driven strategic pivots toward telemedicine and faster therapeutics monetization.

• SPAC merger (June 2021) created public Class A float and preserved founder control via Class B
• Lemonaid Health acquisition ($400 million) signaled move into personalized healthcare
• Reverse split (1-for-20) in late 2024 aimed to maintain NASDAQ listing
• Institutional ownership down to ~28% by 2025, raising privatization discussion

For context on competitors and market positioning that affect investor sentiment and 23andMe parent company comparisons, see Competitors Landscape of 23andMe

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

As of late 2024 and through 2025 the board was reconstituted after a mass resignation; Anne Wojcicki remains the dominant voting controller and the board composition reflects new appointees but voting power remains concentrated.

The company’s governance uses a dual-class share structure: Class B shares carry ten votes per share and Class A carry one vote, a framework that centralizes control despite dispersed economic ownership and ongoing debates about accountability and strategy.

Board Control and Recent Crisis

The dual-class structure gave Anne Wojcicki overwhelming control; a September 2024 crisis saw all seven independent directors resign, briefly leaving Wojcicki as sole director.

• Class B = ten votes per share; Class A = one vote per share
• Wojcicki holds the bulk of Class B shares, ~90% voting power as of 2025
• Fiscal year 2024 net losses exceeded $600 million, fueling activist investor criticism
• Board reconstituted late 2024 but strategic control unchanged

The concentrated voting power makes hostile takeovers virtually impossible and prevents board- or shareholder-driven leadership changes, affecting negotiations around possible private transactions and ongoing discussions about the company’s strategy, including ties to pharmaceutical partners and prior transactions; see Mission, Vision & Core Values of 23andMe for related context.

23andMe Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Recent ownership moves at 23andMe center on founder Anne Wojcicki’s late‑2024 push to take the company private, reflecting a shift toward consolidated, founder-led control as institutional investors reduce exposure to consumer genomics volatility.

Ownership trends affect the 23andMe ownership narrative: founder control, ongoing privatization attempts, and a shift from public investor expectations toward operational focus on clinical assets and subscription revenue.

Privatization bid

Anne Wojcicki pursued buying outstanding shares in late 2024 into 2025 to realign strategy away from public markets.

Cost and headcount cuts

Company cut almost 40% of staff and targets reduced operating costs from an annual spend near $500,000,000.

Subscription focus

23andMe is pushing the 23andMe+ model to reach 1,000,000 subscribers in 2025 to shore up recurring revenue.

M&A and data concerns

Strategic acquisition by a major pharma remains possible but is constrained by regulatory and privacy issues around the 15 million‑person database.

For additional context on corporate positioning and market strategy, see Marketing Strategy of 23andMe.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE